Prognostic impact of neoadjuvant therapy vs upfront surgery in patients with huge hepatocellular carcinoma undergoing curative resection

doi:10.3748/wjg.122833

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 33, Issue 2

This Article

(2)

(0)

(18)

Peer-Review Report of This Article

Supplementary Materials of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2027. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jan 14, 2027; 33(2): 122833
Published online Jan 14, 2027. doi: 10.3748/wjg.122833

Open in New Tab Full Size Figure Download Figure

Figure 1 Selection of the study population. HCC: Hepatocellular carcinoma.

Open in New Tab Full Size Figure Download Figure

Figure 2 Kaplan-Meier curves of survival outcomes in patients with huge hepatocellular carcinoma. A and B: Recurrence-free survival (RFS) and overall survival (OS) in the neoadjuvant treatment group vs the upfront surgery group; C and D: RFS and OS in patients with and without major pathologic response/pathologic complete response after neoadjuvant therapy. RFS: Recurrence-free survival; OS: Overall survival; MPR: Major pathologic response; pCR: Pathologic complete response after neoadjuvant therapy.

Open in New Tab Full Size Figure Download Figure

Figure 3 Forest plot of subgroup analysis by baseline characteristics for recurrence-free survival and overall survival. PVTT: Portal vein tumor thrombosis; HVTT: Hepatic vein tumor thrombus; BCLC: Barcelona Clinic Liver Cancer; HBeAg: Hepatitis B e antigen; AFP: Alpha-fetoprotein.

Citation: Lang MR, Han RY, Zhu FY, Wang ZH, Zhai JX, Luo M, Hu YW, Tao CC, Siqin TN, Sun J, Lu ZY, Zhao JJ, Tong JX, Wang X, Cao DY, Wang LM, Rong WQ, Wu JX, Meng X, Wang HG. Prognostic impact of neoadjuvant therapy vs upfront surgery in patients with huge hepatocellular carcinoma undergoing curative resection. World J Gastroenterol 2027; 33(2): 122833
URL: https://www.wjgnet.com/1007-9327/full/v33/i2/122833.htm
DOI: https://dx.doi.org/10.3748/wjg.122833

Lang MR, Han RY, Zhu FY, Wang ZH, Zhai JX, Luo M, Hu YW, Tao CC, Siqin TN, Sun J, Lu ZY, Zhao JJ, Tong JX, Wang X, Cao DY, Wang LM, Rong WQ, Wu JX, Meng X, Wang HG. Prognostic impact of neoadjuvant therapy vs upfront surgery in patients with huge hepatocellular carcinoma undergoing curative resection. World J Gastroenterol 2027; 33(2): 122833 [DOI: 10.3748/wjg.122833]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.